Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IKS 01

Next Previous
Search
Drug Profile

IKS 01

Alternative Names: IKS-01

Latest Information Update: 28 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iksuda Therapeutics; IONTAS
  • Developer Iksuda Therapeutics
  • Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Pyridines
  • Mechanism of Action Alkylating agents; DNA damage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
  • 26 Oct 2019 Pharmacodynamics data from a preclinical trial in solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2019)
  • 04 Oct 2019 IKS 01 is available for licensing as of 04 Oct 2019. https://iksuda.com/partnerships/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top